Relmacabtagene Autoleucel in Patients With LBCL

Status Recruiting

Clinical Trial Summary

To evaluate the efficacy and safety of Relmacabtagene autoleucel for the treatment of adult patients with relapsed or refractory (r/r) large B-cell lymphoma (LBCL) in real-world

Clinical Trial Description

This is a post-marketing, multicenter, observational real-world study, including prospective and retrospective studies. The purpose of this study is to collect efficacy and safety data over a 6-month period following treatment of adult patients with r/r LBCL with Relmacabtagene autoleucel. The treating physicians in the study will determine the most appropriate diagnostic and therapeutic regimen for their patients based on clinical practice.There will be no therapeutic intervention as a result of this study. There will be no subgroups of any kind in this study, and subgroup analyses will be performed based on the actual data collected during the analysis. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06142175
Study type	Observational
Source	Shanghai Ming Ju Biotechnology Co., Ltd.
Contact	Medical JWCAR029, PhD
Phone	+86 21 50464201
Email	JWCAR029Medical@jwtherapeutics.com
Status	Recruiting
Phase
Start date	December 28, 2022
Completion date	December 31, 2024

View Details

See also
Status	Clinical Trial	Phase
Withdrawn	`NCT05929716` - An Open-Label, Single Center Phase 2 Study of Magrolimab, Rituximab and Radiation as Bridging Strategy Before CAR T-Cell Therapy in Patients With Relapsed or Refractory Large B-cell Lymphoma	Phase 2
Recruiting	`NCT05464719` - A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy	Phase 2
Recruiting	`NCT06047080` - An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma	Phase 3
Active, not recruiting	`NCT04566978` - 89Zr-DFO-REGN3767 in PET Scans in People With Diffuse Large B Cell Lymphoma (DLBCL)	Early Phase 1
Recruiting	`NCT06104592` - Single-Arm Comprehensive Ablative Bridging Irradiation I Prior to CD19 CAR-T In High-Risk R/R LBCL	Phase 2
Recruiting	`NCT04889716` - CAR-T Followed by Bispecific Antibodies	Phase 2
Recruiting	`NCT04250324` - Study of Safety and Efficacy of BZ019 in (R/R) Large B-cell Lymphoma	Phase 1
Recruiting	`NCT05326243` - Phase 1/2 Study of CD19 Chimeric Antigen Receptor T-cell (CD19 CAR-T; PL001) for Relapsed or Refractory B-cell Lymphoma	Phase 1/Phase 2
Recruiting	`NCT05794958` - Evaluate Safety of Axicabtagene Ciloleucel Reinfusion (Axi-Cel-2) in Patients With Relapsed and/or Refractory Second Line High-Risk Non-Hodgkin Lymphoma After Standard of Care Axi-Cel	Phase 1
Recruiting	`NCT06285422` - Study Evaluating SC262 in Subjects With r/r Non-Hodgkin's Lymphoma (VIVID)	Phase 1
Recruiting	`NCT05404048` - PD-L1 PET-imaging During CAR T-cell Therapy	Phase 2
Recruiting	`NCT06375733` - A Study of GFH009 in Combination With Zanubrutinib in Subjects With Relapsed or Refractory DLBCL	Phase 1/Phase 2
Recruiting	`NCT05887167` - Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies	Phase 1
Recruiting	`NCT05648019` - CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory B-Lineage Leukaemia / Lymphoma - A Feasibility Protocol	Phase 2
Recruiting	`NCT05643742` - A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies	Phase 1/Phase 2
Recruiting	`NCT05820841` - Acalabrutinib in Combination With R-miniCHOP in Older Adults With Untreated Diffuse Large B-Cell Lymphoma	Phase 3
Recruiting	`NCT05472610` - Study of Efficacy of BZ019 in Large B-cell Lymphoma	Phase 2
Recruiting	`NCT03960840` - Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, ALL and 1L HR LBCL	Phase 1/Phase 2
Recruiting	`NCT06356129` - Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma	Phase 3
Recruiting	`NCT05665062` - Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies	Phase 1